Skip to main content

Lupus

      Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if the

      Akhil Sood MD AkhilSoodMD

      10 months 3 weeks ago
      Renal biopsies, while painful, remain the gold standard for diagnosing and classifying lupus nephritis. But what if there are less-invasive methods? In this article, I highlight key abstracts exploring innovative approaches. https://t.co/ZInKmVS2Gn @RheumNow #ACR24
      Can you build systems that stop that ANA neg ENA pos anxiety? Plus $$?

      Lehigh Valley, Allentown, PA:
      lab would run ENA+

      David Liew drdavidliew

      10 months 3 weeks ago
      Can you build systems that stop that ANA neg ENA pos anxiety? Plus $$? Lehigh Valley, Allentown, PA: lab would run ENA+dsDNA automatically, but only when ANA >1:80 (i.e. leave the ENA order to the lab) first voluntary, then compulsory it's possible! #ACR24 ABST1931 @RheumNow https://t.co/UQjWwve7DV
      ANA neg, but ENA pos
      should we care about that result?

      PPV 5.5% here
      (similar to 6% prev @EricFMorand: https://t.co/Hya

      David Liew drdavidliew

      10 months 3 weeks ago
      ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey
      VERY exciting SLE update from Fava et al.Machine learning used to generate urinary protein panel predictive of intra-r

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago

      VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

      What a result!!!

      Crowed split 49% against and 51% for MCTD as a unique disease entity

      Given pre-debate poll of >70%

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP
      The anti-MCTD group strikes back

      Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD

      Majority of p

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y
      Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato

      Expansion of prior publicati

      Mike Putman EBRheum

      10 months 3 weeks ago
      Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
      On now: The Great Debate - is MCTD a distinct clinical entity?

      @DrLisaCS reviews the history of MCTD classification cri

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      On now: The Great Debate - is MCTD a distinct clinical entity? @DrLisaCS reviews the history of MCTD classification criteria and its evolution Kasukawa criteria may be most sensitive in one cohort @RheumNow #ACR24 https://t.co/rDHafZVL1I
      Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (

      Akhil Sood MD AkhilSoodMD

      10 months 3 weeks ago
      Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc
      Is there a less invasive approach to evaluate lupus nephritis?

      Abstract 1683 highlights the potential role of 68Ga-FAPI

      Akhil Sood MD AkhilSoodMD

      10 months 3 weeks ago
      Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24
      Will my patient with lupus nephritis respond well to induction therapy?

      Abstract 1685: Aundhia et al demonstrate the pr

      Akhil Sood MD AkhilSoodMD

      10 months 3 weeks ago
      Will my patient with lupus nephritis respond well to induction therapy? Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V) @RheumNow #ACR24 https://t.co/JBldrrwUhN
      Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE
      Belimumab ~ 600% increase

      Bella Mehta bella_mehta

      10 months 3 weeks ago
      Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF
      ×